Product logins

Find logins to all Clarivate products below.


Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of MRSA for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s MRSA forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of MRSA events per year?
  • Of all people diagnosed with MRSA, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MRSA over the forecast period?

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to Microsoft Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following MRSA patient populations:

  • Diagnosed MRSA events by treatment.
  • Diagnosed MRSA events.
  • Diagnosed MRSA events by bloodstream infection (BSI).
  • Diagnosed MRSA events by complicated intra-abdominal infection (cIAI).
  • Diagnosed MRSA events by skin and skin structure infection (SSSI).
  • Diagnosed MRSA events by hospital-acquired pneumonia (HAP).
  • Diagnosed MRSA events by healthcare-acquired pneumonia (HCAP).
  • Diagnosed MRSA events by nosocomial pneumonia (NP).
  • Diagnosed MRSA events by surgical site infection (SSI).
  • Diagnosed MRSA events by SSSI and complicated skin and skin structure infection (cSSSI).
  • … and more (details available on request).

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…